Dynamic Thoracic Impedance as a Marker for Heart Failure Decompensation: A Pilot Trial of the "Dynamic Thoracic Impedance Bed Rest Test"
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Heart Failure; With Decompensation
- Sponsor
- Charles Porter, MD
- Enrollment
- 11
- Locations
- 1
- Primary Endpoint
- Change from sitting to supine to standing in thoracic impedance
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
This pilot study proposes to perform measurements of approved thoracic impedance technology that will help answer questions in patients with decompensated heart failure.
Detailed Description
Improved metrics derived from the transthoracic impedance (Z) available from implanted Medtronic devices may provide more sensitive indicators of the state of compensation for heart failure patients. Quantification of specific data may provide new information that can improve quality of life for patients and offer vital information to clinicians regarding the adequacy of inpatient and outpatient assessment and management of acute decompensated heart failure.
Investigators
Charles Porter, MD
Clinical Associate Professor
University of Kansas Medical Center
Eligibility Criteria
Inclusion Criteria
- •Patients with systolic dysfunction
- •Able to provide informed consent
- •Have a Medtronic manufactured device with Thoracic Impendence Monitoring capabilities
Exclusion Criteria
- •Patients with severe congestive heart failure who are intubated
- •Patients who are oxygen dependent on continuous positive or bilevel positive ventilation
- •Inability to tolerate postural variations due to congestive heart failure or other medical or surgical condition.Unable to complete proposed testing
- •Subjects who cannot giveWill not give written, informed consent on their own behalf
Outcomes
Primary Outcomes
Change from sitting to supine to standing in thoracic impedance
Time Frame: Baseline, 30 Days
thoracic impedance will be measured at each position at baseline visit then again at the follow-up visits through 30 days
Secondary Outcomes
- Rate of change in thoracic impedance(Baseline, 30 days)